HighTower Advisors’s Context Therapeutics CNTX Stock Holding History

HighTower Advisors’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$37.8K	Buy	125,965 +113	+0.1%	+$56	﹤0.01%	3761
2026 Q2	$69.7K	Sell	125,852 -300	-0.2%	-$608	﹤0.01%	3696
2026 Q1	$331K	Buy	126,152 +300	+0.2%	+$701	﹤0.01%	3083
2025 Q4	$185K	Hold	125,852	–	–	﹤0.01%	3400
2025 Q3	$122K	Hold	125,852	–	–	﹤0.01%	3506
2025 Q2	$82.5K	Hold	125,852	–	–	﹤0.01%	3500
2025 Q1	$77K	Hold	125,852	–	–	﹤0.01%	3402
2024 Q4	$132K	Hold	125,852	–	–	﹤0.01%	3312
2024 Q3	$247K	Hold	125,852	–	–	﹤0.01%	2967
2024 Q2	$252K	Hold	125,852	–	–	﹤0.01%	2859
2024 Q1	$174K	Hold	125,852	–	–	﹤0.01%	3025
2023 Q4	$142K	Hold	125,852	–	–	﹤0.01%	3106
2023 Q3	$190K	Hold	125,852	–	–	﹤0.01%	2934
2023 Q2	$201K	Hold	125,852	–	–	﹤0.01%	2865
2023 Q1	$71K	Hold	125,852	–	–	﹤0.01%	2999
2022 Q4	$82K	Hold	125,852	–	–	﹤0.01%	2964
2022 Q3	$140K	Hold	125,852	–	–	﹤0.01%	2692
2022 Q2	$267K	Buy	+125,852	New	+$236K	﹤0.01%	2436

Other funds holding CNTX

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

HighTower Advisors's CNTX Position: Q3 2026 in Review

HighTower Advisors increased its Context Therapeutics (CNTX) stake by 0.09% in Q3 2026, buying an estimated $56 and bringing the position to 125,965 shares worth $37.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3761.

HighTower Advisors first reported a position in CNTX in Q2 2022 and has held it in 18 quarters since. The position peaked at $331K in Q1 2026. 59 funds tracked by Wall St. Rank hold CNTX as of Q3 2026.

HighTower Advisors held 125,965 shares of Context Therapeutics worth $37.8K as of Q3 2026.
HighTower Advisors bought 113 Context Therapeutics shares in Q3 2026, an estimated $56.
Context Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q3 2026, its #3761 holding.
HighTower Advisors first reported a position in Context Therapeutics in Q2 2022 and has held it in 18 quarters since.
HighTower Advisors's Context Therapeutics position peaked at $331K in Q1 2026.
59 funds tracked by Wall St. Rank held Context Therapeutics as of Q3 2026.

Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.